MB-07811

在由制药巨头主导的代谢疾病治疗领域，维京疗法（Viking Therapeutics, VKTX）基于其差异化的科学平台与临床开发策略，展现出成为重要市场参与者的潜力。公司的核心管线聚焦于甲状腺激素受体（THR）及肠促胰岛素通路，其在肥胖症与代谢功能障碍相关脂肪性肝炎（MASH）的中期临床试验中，已获得超越早期候选药物或可与现有疗法参照的积极数据。从临床验证的疗效、基于机制设计的差异化优势，到前瞻性的商业化准备，维京疗法正在系统性地为其产品未来可能的上市构建基础。 核心代谢管线已获临床数据有力验证 维京疗法的两大核心代谢管线资产，已在中期临床试验中展现出具有竞争力的效力和广泛的代谢获益，这构成了其后续开发价值的实证基石。公司的开发策略并非简单跟随，而是通过精准的受体靶向与创新的药物设计，旨在满足现有疗法未能完全覆盖的临床需求。具体而言，其GLP-1/GIP双重激动剂VK2735在减重速度与代谢指标改善上表现突出，而肝脏选择性THR-β激动剂VK2809则在MASH的组织学缓解与心血管代谢获益上提供了差异化的证据。 差异化机制设计构成长期竞争力的核心 维京疗法管线资产的差异化优势，根植于其对受体生物学与药物作用机制的精准设计，旨在最大化治疗效益并系统性地规避已知副作用。此类设计在临床数据中已得到初步验证。VK2735通过双重激动机制试图提升单一靶点药物的疗效天花板，而VK2809则通过组织选择性激活避免传统甲状腺激素药物的全身性毒性。 商业化布局为产品上市构建实质性基础 在推进临床研究的同时，维京疗法正通过供应链建设与关键人才引进，系统性地构建其产品未来上市所需的商业化运营能力。对于一家临床阶段的生物技术公司，提前解决制造产能瓶颈并组建有经验的商业领导团队，是降低未来执行风险、提升自身战略选择权的关键举措。 提前锁定大规模产能是应对代谢药物市场供应挑战的先手棋。多肽类药物的原料药（API）生产和制剂填充能力已成为全球范围内的稀缺资源。2025年3月，维京疗法与合同开发生产组织（CDMO）CordenPharma签署了一项广泛的长期协议。根据协议，维京疗法将在2025年至2028年间预付1.5亿美元，以锁定专用产能。此产能规划旨在每年支持超过1亿支自动注射器或预灌封注射器的生产，以及超过10亿片口服片剂的生产。此类“从原料药到成品”的垂直整合供应链安排，旨在确保VK2735在未来获批后能够避免出现如当前GLP-1药物所面临的供应短缺问题。 任命资深首席商业官标志着商业化准备进入新阶段。2026年1月，维京疗法任命Neil Aubuchon为首席商业官（CCO）。Aubuchon拥有在礼来工作17年以及在安进担任全球营销主管的行业经验，其专业背景覆盖心血管、代谢及罕见病领域。他的核心职责包括领导VK2735的未来市场策略制定、定价与医保准入规划。在诺和诺德与礼来主导的市场环境中，制定有效的市场进入与差异化竞争策略至关重要。Aubuchon的加入，被市场解读为维京疗法正严肃筹备独立商业化路径，或旨在增强其在潜在业务发展谈判中的议价能力。 清晰战略定位应对激烈市场竞争 面对由制药巨头主导的代谢疾病治疗市场，维京疗法选择了一条注重给药灵活性、患者耐受性与内部管线协同潜力的差异化竞争路径。公司的战略体现在“注射+口服”的剂型组合策略，以及其内部管线资产之间潜在的协同效应上。 “注射+口服”的剂型组合旨在针对治疗的不同阶段与患者偏好。维京疗法同时开发VK2735的皮下注射剂型和口服片剂。注射剂型在VENTURE试验中展示了强效的诱导减重能力。而口服剂型在另一项Phase 2研究中，每日一次给药在13周时亦实现了显著的体重减轻。该口服剂型研究中因不良事件导致的中断率较高（VK2735组为29%，安慰剂组为13%），且多数为轻度至中度的胃肠道反应，公司将此归因于试验中采用的快速剂量递增方案。为探索长期维持策略，公司已完成了VK2735维持剂量研究的患者招募。此种“注射剂型用于快速有效诱导减重，口服剂型或较低剂量/频率的注射用于长期维持”的策略，其有效性尚待后续临床数据验证。 内部管线协同潜力为长期价值创造提供可能。维京疗法同时拥有针对不同通路的代谢疾病资产，这为其探索内部联合疗法创造了条件。在MASH治疗领域，联合用药被认为是未来更有效管理这一复杂疾病的方向。例如，GLP-1类药物与THR-β激动剂的联用，可能同时针对代谢异常、脂肪变性及纤维化等多个病理环节。维京疗法无需依赖外部授权即可探索此类内部组合，在研发成本和协同开发效率上具备潜在优势。此外，公司还有针对X-连锁肾上腺脑白质营养不良（X-ALD）的罕见病管线VK0214，该药物同样基于TRβ激动机制，目前已获得初步积极生物标志物数据，展示了公司技术平台的外延能力。 以上是久谦的生物医药研究团队本次针对维京疗法的主要内容。之后我们还会继续推出一系列海外生科公司前沿生物医药研究文章。获取更多深度解析，敬请关注我们的公众号。我们将为您带来更多独家的海外创新药数据解读、管线与机制拆解、真实世界研究与交易案例分析与前沿趋势研判，助您保持领先认知，掌握全球生物医药信息差。 我们自 2023 年起 开始 持续、系统性地追踪 海外生物医药领域的 创新药研发演进，重点覆盖 创新药物作用机制（MOA）、平台型技术路径 及其 临床与商业化验证进展，涵盖 上百家欧美及其他海外市场的主流 / 前沿生物科技公司。 我们已逐步构建起一套 以机制可重复性与商业可扩展性为核心 的研究分析框架，完善了针对不同 技术平台、适应症与研发阶段 的 多维度评估 指标，并基于 大量横向机制对比 与 临床、BD 及商业化场景的交叉验证，沉淀出对 技术成熟度、应用边界 与 长期价值创造潜力 的 专业洞见。 关于我们： 我们是久谦旗下的生物医药研究团队，专注于创新药研发、生命科学工具、医疗技术平台及生物医药产业链等领域的研究，提供包含但不限于商业尽职调查、管线与机制评估、竞争格局分析、行业与赛道研究等服务类型。我们致力于 对早期技术路径与行业演进过程进行系统性研究与持续跟踪，助力投资人与企业在关键技术周期中形成认知优势与高质量决策支持。我们相信，唯有基于一线研究与数据与事实驱动的真实洞察，才能为客户提供真正可落地、可验证的研究结论。 若您有意向与我们进一步交流或合作，请扫描下方二维码联系我们： 您最看好哪个代谢疾病治疗方法？您对维京疗法有何见解？欢迎在评论区与我们交流！

iStock, Volodymyr Kryshtal After last year’s ‘stampede’ for FGF21 assets, the focus for the metabolic dysfunction-associated steatohepatitis space has shifted toward differentiated approaches, such as THR-β agonists and combination treatments, that seek to mirror the commercial success of Madrigal’s Rezdiffra. Before Madrigal’s Rezdiffra, the quest for a cure for metabolic dysfunction-associated steatohepatitis was a veritable graveyard for drug developers. However, the 2024 approval of that first drug for the inflammatory liver disease demonstrated to the pharma industry that the feat was possible. Not only that, but Madrigal proved it could be lucrative. In November 2025, the company announced in its third-quarter financial update that Rezdiffra had generated revenues of $287 million, just six quarters after its launch. Altogether, the product has amassed $817 million in revenue for its maker. This commercial success has not gone unnoticed, with three Big Pharma acquisitions in the MASH space in 2025, all worth billions of dollars. GSK began the rush in May by acquiring the investigational FGF21 analog efimosfermin alfa from Boston Pharmaceuticals for $1.2 billion upfront. Then, in September, Roche snapped up 89bio and another FGF21 analog pegozafermin for around $3.5 billion. Novo Nordisk followed weeks later with a $5.2 billion deal for Akero Therapeutics . The spate of acquisitions—all focused on FGF21 analogs—was centered on the success of Akero Therapeutics’ efruxifermin, which, in January 2025, showed positive long-term data in a mid-stage trial. “I think that really set off the stampede because there were very few FGF21 assets in development,” Edward Nash, managing director at Canaccord Genuity, told BioSpace . “This caused a big pharma reaction of, ‘Wait a minute, we need one of those too because we have a metabolic franchise and we need to be able to compete, especially given the data seen to date in the FGF21 space.’” This, alongside the approval of Novo Nordisk’s GLP-1 weight-loss blockbuster Wegovy for MASH, has led to the market opening up, and now, more companies want in, Nash said. All of this activity means the overall MASH landscape has changed significantly in the past year . With the key FGF21 developers off the market, there is an increased focus on the other assets in the field’s late-stage pipeline. Here are four candidates, each with differentiated mechanisms of action, that Big Pharma companies could have in their sights in 2026. Policy FDA Approves Madrigal’s Rezdiffra as First MASH Therapy Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) is the first-ever approved therapy for metabolic dysfunction-associated steatohepatitis—a decision experts say could signal a sea change in treatment of the disease. March 14, 2024 · 6 min read · Jill Neimark Inventiva Homes In On Potential Next Oral MASH Drug Inventiva’s upcoming Phase III readout for pan-PPAR agonist lanifibranor is “the biggest event in the MASH space” this year, according to Nash. “It’s been a long trial, and it’s been long-awaited by the Street,” he said. “Depending on the data, [Inventiva] could definitely become another takeover candidate.” The French biotech is now solely focused on lanifibranor after halving its workforce and stopping all preclinical research not related to the drug to help fund its development in February 2025. This singular focus will help push the drug through its Phase III trial, with Inventiva poised to publish topline results from the NATiV3 trial in the second half of 2026. With these data expected, “lanifibranor could potentially be the next oral therapy approved for the treatment of patients with MASH,” CEO Frederic Cren said in a statement in April 2025. Lanifibranor is an oral small molecule that activates three peroxisome proliferator-activated receptor (PPAR) isoforms. Through the activation of these isoforms, Inventiva aims to address the key drivers of the disease, including inducing anti-fibrotic, anti-inflammatory and beneficial metabolic changes. In the NATIVE Phase IIb trial , reported in June 2020, lanifibranor achieved statistically significant MASH resolution and fibrosis improvement, with 42% of patients who received a 1200 mg dose seeing fibrosis improvement vs. 24% of placebo comparators after 24 weeks. The path to this year’s Phase III readout has not been straightforward for Inventiva. In February 2024 , the company voluntarily suspended screening and enrollment of patients in NATiV3 after a patient exhibited severely elevated aminotransferase levels. Now, Inventiva expects the results from NATiV3, if positive, to form the basis for a submission for regulatory approval. Viking Still Up For Grabs Viking Therapeutics has long attracted significant interest from Big Pharma. With pipeline assets that target both obesity and MASH, analysts have marked the biotech as one likely to draw suitors. For MASH, the company is developing VK2809, an oral thyroid hormone receptor-beta (THR-β) agonist. In the Phase IIb VOYAGE trial , VK2809 demonstrated a 37%-55% mean reduction in liver fat, with up to 75% of patients reaching MASH resolution without fibrosis worsening, according to data released in November 2024. In addition to these outcomes, the drug also demonstrated lipid-lowering effects and minimal side effects, Brian Lian, CEO of Viking, told BioSpace in an email. The overall body of evidence for VK2809 makes it “highly competitive” against both marketed products and drug candidates for MASH, he added. While Lian has previously stated that Viking would be open to partnering on the asset and confirmed that the company is still exploring partnering opportunities—he previously said that having a partner is not mandatory in order to bring the product to the market. Earnings MASH, Metsera Deals Send Analysts Marauding to Viking Viking Therapeutics CEO Brian Lian is watching the growth of interest in MASH and obesity but prepared to go it alone. October 23, 2025 · 6 min read · Annalee Armstrong Altimmune Open to Partnering Pemvidutide But Could Go It Alone Altimmune’s pemvidutide stands apart from others in the MASH pipeline due to its ability to preserve lean muscle mass, as well as ensuring MASH resolution and weight loss, a company spokesperson told BioSpace in an email. Pemvidutide is a weekly injectable GLP-1/glucagon dual receptor agonist that last month received the FDA’s Breakthrough Therapy Designation for MASH. This follows the November release of Phase IIb data from Altimmune’s IMPACT study, which showed that 52% of patients achieved MASH resolution without worsening of fibrosis, as well as improvements to liver fat content and weight loss. Altimmune is in a similar position to Viking, as both companies have the data to progress their drugs into Phase III, but may not begin those trials until they can find a partner, Nash said. “These two companies are all in on obesity, and that treatment area is already a big enough nut to crack,” he added. “To try to do that and run a MASH trial at the same time, I think you’re going to get a lot more bang for your buck if your molecule is differentiated in obesity.” The Altimmune spokesperson countered this, however, saying that independently bringing the asset forward in MASH is a “legitimate path forward.” However, they also noted that Altimmune remains open to any opportunity “that adds value, including partnerships.” Sagimet Looks to Combo FASN Inhibitor For Optimum Effect Like pemvidutide, Sagimet Biosciences’ denifanstat, an oral, once-daily fatty acid synthase (FASN) inhibitor that blocks the production of new fat in the liver, holds FDA Breakthrough Therapy Designation in MASH. Unlike Altimmune, however, Sagimet is not considering pursuing a Phase III trial alone, according to Nash. Instead, the California-based company is looking to cement its drug as a validated part of a combination therapy. In line with this, Sagimet released data in December from a Phase I trial that featured denifanstat paired with Rezdiffra, the current market leader. The trial showed that the combination was well-tolerated, and Sagimet plans to advance denifanstat into Phase II efficacy trials for MASH patients with F4 fibrosis. The combined treatment could boost fibrosis reduction more than Rezdiffra alone, Nash said. This type of combination approach is likely to be the future of MASH treatments because the disease is multifactorial, he added, with the main two targets being liver fat and fibrosis. So far, the marketed drugs— Rezdiffra and Wegovy—and the investigational pipeline have not proven outstanding at hitting both of these targets, making a combination treatment approach logical, Nash said. It seems the same could be true for the companies themselves, with partnering and M&A the likeliest outcome for the smaller players in the MASH landscape. “It’s hard to be successful as a standalone company,” Nash said. “There’s usually only one company when that happens, like Madrigal. I think we’re going to have one, maybe two biotechs, that can do it—after that, it’s going to be Big Pharma taking them in and developing them.”